Abstract Details

Title Real World Relapse Rates of Glatiramer Acetate Patients Switching to Fingolimod or Interferon Beta-1a Versus Remaining on Glatiramer Acetate

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 181

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
Tara Nazareth (Mallinckrodt Pharmaceuticals)	No disclosure on file
	No disclosure on file
Kristen Johnson, PhD (Novartis)	No disclosure on file
John Ko, PharmD, MS (Alnylam)	Dr. Ko has received personal compensation for serving as an employee of Alnylam Pharmaceuticals. Dr. Ko has received personal compensation for serving as an employee of Novartis. Dr. Ko has received stock or an ownership interest from Alnylam Pharmaceuticals. Dr. Ko has received stock or an ownership interest from Novartis.
Emily A. Johnson	No disclosure on file
	No disclosure on file
Rahul Sasane, PhD (Cerevel Therapeutics)	Dr. Sasane has received personal compensation for serving as an employee of Cerevel Therapeutics. Dr. Sasane has stock in Cerevel Therapeutics.

��ɫ��